Search Results for "treatment guidelines"
Search again or select article below to purchase. Single article price: $45. Order 3 or more at one time and receive a 10% discount.
Sort by relevance | Sort by date
Searched for treatment guidelines. Results 141 to 150 of 155 total matches.
Drugs for Gout
The Medical Letter on Drugs and Therapeutics • Oct 30, 2023 (Issue 1688)
flares, development of tophi, and
joint damage.1
TREATMENT OF FLARES
Treatment of a gout flare should ...
Drugs for gout are used to reduce the pain and
inflammation of acute flares, decrease the frequency
of exacerbations, and lower serum urate levels to
prevent recurrent flares, development of tophi, and
joint damage.
Med Lett Drugs Ther. 2023 Oct 30;65(1688):169-75 doi:10.58347/tml.2023.1688a | Show Introduction Hide Introduction
IV Amisulpride (Barhemsys) for Postoperative Nausea and Vomiting
The Medical Letter on Drugs and Therapeutics • Dec 28, 2020 (Issue 1614)
and treatment of
postoperative nausea and vomiting (PONV) in adults.
It is the first antiemetic to be approved ...
The FDA has approved IV amisulpride (Barhemsys –
Acacia), a selective dopamine-2 and -3 (D2/D3) receptor
antagonist, for prevention and treatment of postoperative
nausea and vomiting (PONV) in adults. It is the first
antiemetic to be approved for rescue treatment of
PONV in patients who have symptoms despite receiving
antiemetic prophylaxis. Oral formulations of amisulpride
are available in Europe for treatment of schizophrenia
and acute psychotic episodes.
IV Artesunate for Severe Malaria
The Medical Letter on Drugs and Therapeutics • Aug 10, 2020 (Issue 1604)
. Treatment of malaria: guidelines for clinicians (United
States). Available at: www.cdc.gov/malaria ...
Artesunate for injection (Amivas LLC), a semi-synthetic
artemisinin derivative, is now approved
by the FDA for initial (induction) treatment of severe
malaria in children and adults. It has been available
from the CDC on a compassionate use basis since
2007. Artemether/lumefantrine (Coartem), another
artemisinin-based drug, was approved earlier for oral
treatment of uncomplicated Plasmodium falciparum
malaria. IV artesunate is now the only FDA-approved
injectable antimalarial drug available in the US; IV
quinidine has been discontinued.
Lebrikizumab (Ebglyss) for Atopic Dermatitis
The Medical Letter on Drugs and Therapeutics • Nov 11, 2024 (Issue 1715)
, for treatment of moderate to severe
atopic dermatitis that has not been or cannot be
adequately treated ...
The FDA has approved lebrikizumab-lbkz (Ebglyss –
Lilly), a subcutaneously injected interleukin (IL)-13
antagonist, for treatment of moderate to severe
atopic dermatitis that has not been or cannot be
adequately treated with topical therapy in patients ≥12
years old (weight ≥40 kg). Lebrikizumab is the third
subcutaneously injected human IgG4 monoclonal
antibody to be approved in the US for this indication.
Tralokinumab (Adbry), another IL-13 antagonist, is
also approved for use in patients ≥12 years old, and
dupilumab (Dupixent), an IL-4 and IL-13 inhibitor, is
approved for...
Med Lett Drugs Ther. 2024 Nov 11;66(1715):179-81 doi:10.58347/tml.2024.1715b | Show Introduction Hide Introduction
Drugs for GERD and Peptic Ulcer Disease
The Medical Letter on Drugs and Therapeutics • Apr 04, 2022 (Issue 1647)
infection. Annu Rev Med 2022; 73:183.
26. WD Chey et al. ACG clinical guideline: treatment of
Helicobacter ...
Gastroesophageal reflux disease (GERD) is the most
common GI condition encountered in the outpatient
setting; it affects about 20% of people in the US.
Drugs for Chronic Heart Failure
The Medical Letter on Drugs and Therapeutics • May 26, 2025 (Issue 1729)
or mid-range ejection fraction.1,2
HF WITH REDUCED EJECTION FRACTION
STANDARD TREATMENT — All patients ...
Pharmacologic management of chronic heart failure
(HF) is primarily determined by the patient's left
ventricular ejection fraction (LVEF) and severity of
symptoms. Patients with chronic HF who have an
LVEF ≤40% are considered to have heart failure with
reduced ejection fraction (HFrEF) and those with an
LVEF ≥50% are considered to have heart failure with
preserved ejection fraction (HFpEF). Patients with an
LVEF of 41-49% have heart failure with mildly reduced
or mid-range ejection fraction.
Med Lett Drugs Ther. 2025 May 26;67(1729):81-8 doi:10.58347/tml.2025.1729a | Show Introduction Hide Introduction
Drugs for COPD
The Medical Letter on Drugs and Therapeutics • Sep 02, 2024 (Issue 1710)
for Chronic Obstructive Lung
Disease) guidelines for treatment of COPD were
updated recently.1 Treatment ...
The main goals of treatment of chronic obstructive
pulmonary disease (COPD) are to relieve symptoms,
reduce the frequency and severity of exacerbations,
prevent disease progression, and reduce mortality.
GOLD (Global Initiative for Chronic Obstructive Lung
Disease) guidelines for treatment of COPD were
updated recently. Treatment of acute exacerbations
is not discussed here. Drugs available for treatment
of COPD are listed in Tables 1 and 3.
Med Lett Drugs Ther. 2024 Sep 2;66(1710):137-44 doi:10.58347/tml.2024.1710a | Show Introduction Hide Introduction
Opioids for Pain
The Medical Letter on Drugs and Therapeutics • Dec 12, 2022 (Issue 1665)
Opioids for Pain
A new CDC guideline for prescribing opioids for pain
recently became available.1 ...
A new CDC guideline for prescribing opioids for pain
recently became available. Nonopioid drugs for pain
were reviewed in a previous issue.
Insect Repellents
The Medical Letter on Drugs and Therapeutics • Jul 07, 2025 (Issue 1732)
)
HOMS Bite Blocker BioUD Insect Repellent
and Clothing Treatment
7.75% pump spray 5 hours ▶ Repels ...
The Centers for Disease Control and Prevention
(CDC) and the Environmental Protection Agency (EPA)
recommend using insect repellents to avoid being
bitten by mosquitoes, ticks, and other arthropods
that transmit disease-causing pathogens. Repellents
applied to exposed skin should be used in conjunction
with other preventive measures such as wearing long-sleeved
shirts, pants, and socks and avoiding outdoor
activities during peak mosquito-biting times. Some
insect repellents are listed in Table 1.
Med Lett Drugs Ther. 2025 Jul 7;67(1732):105-9 doi:10.58347/tml.2025.1732a | Show Introduction Hide Introduction
Drugs for Cognitive Loss and Dementia
The Medical Letter on Drugs and Therapeutics • Aug 22, 2022 (Issue 1657)
; it may be a transitional state between the
cognitive changes of normal aging and dementia.1
Treatment of reversible ...
Alzheimer's disease (AD) is the most common
cause of dementia, but cognitive decline is also
associated with other neurological conditions such
as Parkinson's disease, dementia with Lewy bodies,
vascular dementia, and frontotemporal dementia.